dc.creatorSapunar Z,Jorge
dc.creatorMuñoz N,Sergio
dc.creatorVásquez A,Tatiana
dc.date2009-11-01
dc.date.accessioned2017-03-07T16:17:54Z
dc.date.available2017-03-07T16:17:54Z
dc.identifierhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872009001100002
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/399222
dc.descriptionAtypical antipsychotic drugs have less extra pyramidal side effects and are more effective to control the clinical manifestations of schizophrenia. However, their use may be associated to a higher incidence of weight gain, dyslipidemia, metabolic syndrome, glucose intolerance and type 2 diabetes mellitus. We performed a systematic literature search to evaluate the risk of type 2 diabetes mellitus incidence associated to the use of atypical antipsychotic drugs, compared to conventional treatment. If users of all types of atypical antipsychotic drugs are compared with users of conventional treatment, no significant differences in the incidence of type 2 diabetes mellitus were observed. If individual drugs are evaluated, clozapine and risperidone are associated with a higher risk of diabetes than haloperidol. Quetiapine is associated with a lower risk of diabetes than conventional treatment. The quality of the evidence found was low; therefore, new studies should been performed.
dc.formattext/html
dc.languagees
dc.publisherSociedad Médica de Santiago
dc.sourceRevista médica de Chile v.137 n.11 2009
dc.subjectAntipsychotic agents
dc.subjectAripiprazole
dc.subjectDiabetes mellitus
dc.subjectClozapine
dc.subjectOlanzapine
dc.subjectQuetiapine
dc.subjectRisperidone
dc.subjectZiprasidone
dc.subjectZotepine
dc.titleComparación del efecto de la terapia prolongada con antipsicóticos atípicos o convencionales en la incidencia de diabetes mellitus 2: Revisión sistemática y metaanálisis
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución